Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
561-580 of 1,743 trials

Melanoma Treatment: Daromun Injection Study

We are studying whether intratumoral injections of Daromun can help patients with Stage IIIB/C melanoma live longer and reduce the chance of cancer returning after surgery. This trial compares the new treatment to standard surgery and therapy.

Stage III Superficial Spreading Melanoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Non-Small Cell Lung Cancer: Divarasib with Other Therapies

We are studying the safety and effectiveness of divarasib combined with pembrolizumab and chemotherapy in patients with untreated advanced lung cancer that has a KRAS G12C mutation. This research aims to find the best dose and treatment approach.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Zilovertamab Vedotin for Pediatric Cancers

We are studying a new treatment for children and young adults with blood cancers and solid tumors. The trial aims to assess its safety and how well it may work in these young patients.

Blood Cancers and Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPediatrics

MOGAD: Evaluating Satralizumab Treatment

We are studying the effectiveness and safety of satralizumab for patients with MOGAD. This trial compares the new treatment to a placebo to see how well it prevents disease relapses.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)>2 yearsConfirmation phase (III)Post-Trial Drug AccessPartially RemoteNeurologyRheumatology

Immunoglobulin A Nephropathy: Sibeprenlimab Study

We are testing the safety and effectiveness of Sibeprenlimab for people with Immunoglobulin A Nephropathy. This study aims to see how well it works in managing the condition and its impact on kidney health.

IgA Nephropathy>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNephrology

Severe Hyponatremia: DDAVP Treatment Study

We are investigating whether DDAVP can help prevent sodium overcorrection in patients with severe hyponatremia. This study aims to improve safety and outcomes for those experiencing dangerously low sodium levels.

Low Sodium Levels (Hyponatremia)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Ulcerative Colitis: Adalimumab Treatment Comparison

We are comparing a new treatment approach with telemonitoring and education to standard care for patients starting adalimumab. The aim is to see if this helps manage ulcerative colitis more effectively.

Ulcerative Colitis>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Hemophilia B: REGV131-LNP1265 Gene Therapy

We are studying a new gene therapy to see if it is safe and helps adults with Hemophilia B produce a vital clotting factor. The trial will also assess how it affects bleeding events.

Hemophilia B>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Familial Hypercholesterolemia: Inclisiran Safety Study

We are studying the long-term safety and tolerability of inclisiran in individuals with familial hypercholesterolemia who have completed earlier studies. This research aims to understand how well the treatment works over time.

Familial Hypercholesterolemia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Pneumonia Prevention: 20-Valent Pneumococcal Vaccine

We are studying whether a new 20-valent pneumococcal vaccine helps prevent pneumonia in adults aged 65 and older. This trial will assess its effectiveness against specific types of pneumonia caused by certain bacteria.

Community Acquired Pneumonia>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesPulmonology

HER2-Positive Breast Cancer: Trastuzumab and Pertuzumab Study

We are exploring a new treatment approach for patients with HER2-positive unresectable locally advanced or metastatic breast cancer. This study aims to see how well this treatment works and its safety compared to existing options.

HER2-positive Metastatic Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Ongoing Treatment with Durvalumab for Cancer Patients

We are providing continued treatment for patients who have benefited from Durvalumab in a previous study. The focus is on monitoring safety and tolerability during this ongoing care.

Advanced Non-Small Cell Lung CancerPost-Chemotherapy Urothelial CarcinomaExtensive Stage Small-Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

COVID-19 Vaccine: Preventing Type 1 Diabetes in At-Risk Children

We are studying if vaccinating children with a higher genetic risk for type 1 diabetes against COVID-19 can lower their chances of developing diabetes and related autoimmune conditions. This research aims to see if the vaccine can help protect their health.

Risk for Type 1 Diabetes>2 yearsMonitoring phase (IV)11-15 visitsStandard MedicinesCost ReimbursementEndocrinologyInfectious Diseases

Pulmonary Fibrosis: Long-Term Study of BI 1015550

We are investigating the long-term safety and effectiveness of BI 1015550 in patients with pulmonary fibrosis who have previously participated in related studies. This study aims to understand how well the treatment is tolerated and its potential benefits.

Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Long-Term Safety Study of NTLA-2001

We are evaluating the long-term safety and effects of NTLA-2001 in participants who have already received this treatment. This study aims to understand how it impacts their health over time.

Hereditary Amyloidosis>2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNeurology

Multiple Myeloma: Iberdomide with Isatuximab

We are studying whether adding isatuximab to iberdomide helps patients with newly diagnosed multiple myeloma achieve better treatment outcomes after stem cell transplantation.

Multiple Myeloma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Chronic Obstructive Pulmonary Disease: New Inhaler Study

We are evaluating a new inhaler that combines Budesonide, Glycopyrronium, and Formoterol for people with COPD. The goal is to see if it improves heart and lung health compared to current treatments.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePulmonology

Advanced Solid Tumors: TAPISTRY Immuno-Oncology Study

We are testing a new treatment for patients with advanced or metastatic solid tumors that have specific genetic changes. The goal is to see how well it works and how it affects patients' daily lives.

Solid Tumors>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology

B-Cell Malignancies: PIT565 Treatment Study

We are testing a new treatment called PIT565 for patients with relapsed or refractory B-cell malignancies. The goal is to see if it can improve outcomes for these patients.

Relapsed and Refractory B-cell Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukaemia>2 yearsSafety phase (I)Oncology

Chronic Kidney Disease: CKD-bioMatch Study

We are exploring whether a new treatment based on biomarkers can improve kidney function in patients with chronic kidney disease compared to standard care. This study aims to find better ways to manage CKD and its effects.

Chronic Kidney Disease>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementNephrology